The FDA recently released a draft guidance for new process validation. The guidance says that manufacturers would have to increase sampling and testing, and monitor process performance more closely during the early stages of commercial manufacturing, according to the FDA's Guidance for Industry - Process Validation: General Principles and guidance. Once finalized, this guidance replaces the FDA's process validation guidance issued in 1987. The new guidance applies to pharmaceuticals, biologics and active pharmaceutical ingredients. It will cover the 3 stages of process validation — process design, process qualification and continued process verification. Are you ready?
Thursday, January 8, 2009
FDA Draft Guidance On Process Validation
Related Posts:
Medical Devices Containing Antimicrobial Agents - FDA Guidance Pending
FDA Data Guidance - When patients withdraw from clinical trials
View more FDA Guidance Documents (free)
FDA Draft Guidance On Proprietary Names
New FDA Guidance - Residual Solvents in Drug Products
New FDA Guidance - New Contrast Imaging Indication Considerations
New FDA Guidance - cGMP Practice for Phase 1 Investigational Drugs
FDA Guidance Documents - FDA Current Thinking (free)
Sign up for FDA Guidance Documents email updates.
Return Home: http://drughealth.blogspot.com/
Labels:
biologic,
draft,
drug,
fda,
guidance,
health,
monitoring,
pharma,
prescription,
process,
sampling,
testing,
validation
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment